๐TL;DR
- โขFirst-in-class integrin regulator for dry AMD (no approved treatments exist)
- โขMulti-target mechanism addressing oxidative stress and mitochondrial dysfunction
- โขSignificant visual acuity improvement demonstrated in Phase 2a
- โขFavorable safety profile with no drug-related serious adverse events
- โขVEGF-independent mechanism complementary to existing wet AMD treatments
Protocol Quick-Reference
Treatment of intermediate dry age-related macular degeneration
Dosing
Amount
1.0 mg intravitreal injection
Frequency
Every 12 weeks (Phase 2b/3 design)
Duration
52 weeks (Phase 2b/3 primary endpoint)
Administration
Route
IVSchedule
Every 12 weeks
Timing
Intravitreal injection administered by a qualified retinal specialist under sterile ophthalmic conditions. Not a subcutaneous or systemic injection.
Cycle
Duration
52 weeks
Repeatable
Yes
โ๏ธ Suggested Bloodwork (3 tests)
Best corrected visual acuity (BCVA)
When: Baseline and every 12 weeks
Why: Primary efficacy endpoint for visual function
Intraocular pressure (IOP)
When: Post-injection
Why: Monitor for elevated IOP after intravitreal injection
Optical coherence tomography (OCT)
When: Baseline and periodic
Why: Monitor retinal structure and integrity
๐ก Key Considerations
- โInvestigational drug not approved by any regulatory agency; administered only in clinical trial settings
- โIntravitreal injections carry inherent procedural risks including endophthalmitis and retinal detachment
- โPhase 2a results are promising but Phase 2b/3 confirmation trials are ongoing
Subscribe to unlock this content
Get free access to all content plus biweekly research updates.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Scientific Details
- Molecular Formula
- C22H39N9O11S
- Molecular Weight
- 637.66 Da
- CAS Number
- 1307293-62-4
- Sequence
- Gly-Arg-Gly-Cya-Thr-Pro
What is Risuteganib?#
Risuteganib (Luminate, ALG-1001) is a first-in-class synthetic RGD-class peptide developed by Allegro Ophthalmics for the treatment of retinal diseases, primarily intermediate dry age-related macular degeneration (AMD) and diabetic macular edema (DME). It is administered by intravitreal injection and has a retinal half-life of approximately 21 days.
Risuteganib is particularly significant because there are currently no FDA-approved pharmaceutical treatments for intermediate dry AMD, a condition affecting millions of people worldwide and representing a major unmet medical need. While complement inhibitors (pegcetacoplan, avacincaptad pegol) have been approved for geographic atrophy (advanced dry AMD), no treatments address the earlier intermediate stage.
Mechanism of Action#
Risuteganib modulates multiple integrin heterodimers involved in retinal pathology:
- alphaVbeta3: Involved in angiogenesis and oxidative stress response
- alphaVbeta5: Involved in phagocytosis and oxidative stress
- alpha5beta1: Involved in cell adhesion and migration
- alphaMbeta2: Involved in immune cell chemotaxis, inflammation, and phagocytosis
By regulating these integrin pathways, risuteganib addresses multiple pathogenic mechanisms simultaneously:
- Reduces oxidative stress: Protects retinal cells from oxidative damage, a key driver of AMD
- Restores mitochondrial function: Improves mitochondrial health in retinal cells
- Anti-inflammatory: Modulates the immune response via alphaMbeta2 inhibition
- Anti-angiogenic: Reduces pathological blood vessel growth via a VEGF-independent mechanism
- Neuroprotective: Increases Mueller cell viability and reduces retinal cytotoxicity
Clinical Development#
| Trial | Phase | Indication | Status |
|---|---|---|---|
| Phase 2a (US) | Phase 2a | Intermediate dry AMD | Completed (positive) |
| Phase 2b/3 (US) | Phase 2b/3 | Intermediate dry AMD | FDA SPA agreement received |
| Phase 2 | Phase 2 | Diabetic macular edema | Completed |
| China CTA | Phase 2/3 | Intermediate dry AMD | CTA approved |
Important Considerations#
Risuteganib is an investigational drug that has not been approved by any regulatory authority. While Phase 2a results are promising, Phase 2b/3 confirmation trials are needed. Intravitreal injections carry inherent procedural risks including endophthalmitis and retinal detachment.
Key Research Findings#
Safety and Efficacy of Intravitreal Risuteganib for Non-Exudative AMD: A Multicenter, Phase 2a, Randomized, Clinical Trial, published in Ophthalmic Surgery, Lasers and Imaging Retina (Boyer DS et al., 2021; PMID: 34185587):
- The study demonstrated of risuteganib patients gained 8 or more ETDRS letters of 48% at week 28 versus 7% sham at week 12
- The study demonstrated of risuteganib patients gained 15 or more letters of 20% at week 28 versus 0% sham
Related Reading#
Stay current on Risuteganib research
We summarize new studies, safety updates, and dosing insights โ delivered biweekly.
Community Protocols Available
See real-world usage patterns alongside the clinical evidence above. Community-sourced, not clinically verified.
0View community protocolsFrequently Asked Questions About Risuteganib
Explore Further
Related Peptides
View all peptides โBPC-157
BPC-157: Gastric-derived healing peptide guide. Covers tissue repair mechanisms, gut-brain axis effects, tendon and GI healing research, and dosing.
Brimapitide
Brimapitide (AM-111): cell-penetrating JNK inhibitor peptide for sudden hearing loss. Phase 3 HEALOS trial results and intratympanic delivery mechanism.
Cerebrolysin
Cerebrolysin: Brain-derived peptide for stroke and TBI recovery. Covers neurotrophic mechanisms, approvals in 40+ countries, dosing, and safety data.
AOD-9604
AOD-9604: HGH fragment for fat loss research. Covers lipolytic mechanism without IGF-1 effects, weight management data, dosing, and GRAS safety status.
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.
You Might Also Like
Related content you may find interesting